Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

[Osteoarthritis and cellular therapeutics].

Gritten M., Kaux JF.

Narrative Review on Osteoarthritis, Immune Modulation, published in Rev Med Liege (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Rev Med Liege (2026)
Country
Belgium
Reported sample size
—
Source database
PubMed
PMID
41537329

Abstract (original English)

Osteoarthritis, a degenerative disorder of the osteoarticular system, leads to progressive cartilage deterioration, resulting in pain and functional impairment. Its clinical presentation is heterogeneous, reflecting a diversity of phenotypes and molecular profiles. Risk factors include advanced age, female sex, obesity and joint trauma. Among emerging therapeutic strategies, mesenchymal stem cells (MSCs) offer promising prospects. These cells, derived from bone marrow, adipose tissue, and umbilical tissues, exhibit regenerative and immunomodulatory properties. In parallel, MSC-derived exosomes, which carry regenerative bioactive factors, represent another avenue of innovation, though their clinical application still requires further validation. L’arthrose, pathologie dégénérative du système ostéo-articulaire, provoque une détérioration du cartilage, générant douleurs et incapacités fonctionnelles. Sa présentation clinique, polymorphe, découle de multiples phénotypes et profils moléculaires. Les facteurs de risque incluent l’âge avancé, le sexe féminin, l’obésité et les traumatismes articulaires. Parmi les thérapeutiques innovantes, les cellules souches mésenchymateuses (CSM) offrent des perspectives prometteuses. Ces cellules, dérivées de la moelle osseuse, du tissu adipeux et de tissus ombilicaux, présentent des propriétés régénératrices et immunomodulatrices. En parallèle, le

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansOsteoarthritisMesenchymal Stem Cell TransplantationCell- and Tissue-Based TherapyMesenchymal Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research